Progenity is a biotech company with a multi-omics approach.
We are combining genomics, epigenomics, proteomics, and metabolomics to improve the diagnosis and treatment of disease.
About UsTransforming healthcare to be more precise and personal.
Latest News
- Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies October 13, 2021
- Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules October 4, 2021
Featured Publications
- Development of a novel drug delivery system to deliver drugs directly... The DDS2 system could result in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis. Aug 30, 2021
- Targeted delivery of tofacitinib citrate to the site of disease to improve... When delivered to the site of inflammation, liquid drug formulations could result in higher tissue absorption and lower drug exposure. May 20, 2021